Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia We enrolled 16 patients ...

Researchers have identified potential drug targets in glioblastoma cancer stem cells, providing a new approach to treat this ...

The efficacy seen in a small study, especially in GNAS-mutated tumors, could influence care, but the rarity of the cancer is ...

A TYK Medicines Inc. patent discloses tricyclic compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Title: INX-315, an oral, potent and selective CDK2 inhibitor in patients with CDK4/6 inhibitor resistant ER+/HER2- breast cancer or CCNE1 amplified solid tumors: phase 1 monotherapy dose escalation ...

The major focus of our research is on the HIV Tat protein, which is essential for HIV transcription, and on two cellular factors, cyclin T1 and Cdk9, which are necessary for Tat function. We are ...

Current methods targeting cyclin-dependent kinases can be limited by low selectivity and toxicity ... macrocycle platform molecules to achieve our goal of transforming the lives of people living with ...

Geoffrey Shapiro, MD, Ph.D., senior vice president, Development Therapeutics at Dana-Farber Cancer Institute and ... excited to see Circle Pharma’s cyclin A/B RxL inhibitor move into the clinic." ...

For instance, they might say your cancer is stage IIIA. The four letters are A, B, C and D. This tells you how fast-growing (aggressive) your cancer is. A is the least aggressive and D is the most ...

Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected ...